Aberrant expression of peroxiredoxin 1 and its clinical implications in liver cancer

Table 2 Expression of peroxiredoxin 1 protein and its clinical significance

	22 kDa band		P value	50 kDa band		P value
	n	Up-regulated (%)		n	Down-regulated (%)
Gender
Male	26	45.2 (12/26)	1.00	26	69.2 (18/26)	1.00
Female	3	33.3 (1/3)		3	66.7 (2/3)
Age
≥ 60	10	30.0 (3/10)	0.43	10	40.0 (4/10)	0.03
< 60	19	52.6 (10/19)		19	65.5 (16/19)
Tumor size
≤ 3 cm	7	42.9 (3/7)	1.00	7	42.9 (3/7)	0.16
> 3 cm	22	45.5 (10/22)		22	77.3 (17/22)
Differentiation
Well	7	28.6 (2/7)	0.41	7	71.45 (5/7)	1.00
Moderately	18	55.6 (10/18)		18	66.7 (12/18)
Poorly	4	25.0 (1/4)		4	75.0 (3/4)
TNM staging
I-II	20	35.0 (7/20)	0.23	20	70.0 (14/20)	1.00
III-IV	9	66.7 (6/9)		9	66.7 (6/9)
AFP
≥ 200 ng/mL	7	42.9 (3/7)	1.00	7	71.4 (5/7)	1.00
< 200 ng/mL	22	45.5 (10/22)		22	68.2 (15/22)

AFP: α-fetoprotein.